Dexamethasone Sodium Phosphate: Brands, Price & Uses in Bangladesh

Dexamethasone Sodium Phosphate is a water-soluble corticosteroid (glucocorticoid) injection used, per physician direction, for a wide range of conditions. Indications are classified below by strength of evidence.

Established / FDA-approved uses

• Endocrine disorders: primary or secondary adrenocortical insufficiency (used with a mineralocorticoid where applicable), acute adrenal crisis, congenital adrenal hyperplasia
• Severe allergic conditions: anaphylaxis (as an adjunct, not a substitute for epinephrine), severe drug hypersensitivity reactions, severe allergic rhinitis, serum sickness
• Rheumatic and collagen-vascular disorders: as adjunctive short-term therapy in rheumatoid arthritis, acute gouty arthritis, ankylosing spondylitis, systemic lupus erythematosus flares, acute rheumatic carditis
• Severe asthma exacerbations and status asthmaticus (adjunct to bronchodilators)
• Dermatologic conditions: pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, severe psoriasis
• Cerebral edema (associated with brain tumor, neurosurgery, or head injury)
• Hematologic disorders: acquired hemolytic anemia, idiopathic thrombocytopenic purpura in adults
• Ophthalmic inflammatory conditions (severe acute and chronic allergic and inflammatory processes involving the eye)
• Gastrointestinal disease: to tide a patient over a critical period in ulcerative colitis and regional enteritis
• Local (intra-articular/soft-tissue/intralesional) injection for inflammatory conditions such as osteoarthritis, bursitis, tenosynovitis, and keloids

Adjunct uses

• Antiemetic adjunct to prevent chemotherapy-induced nausea and vomiting
• Cerebral edema associated with malignancy, as an adjunct to definitive treatment

Guideline-supported / off-label use (clearly labeled)

• Severe COVID-19 in hospitalized patients requiring supplemental oxygen or ventilatory support — this is an off-label, guideline-driven use (e.g., WHO/NIH treatment guidance) rather than an original FDA-approved indication; the oral/IV dexamethasone regimen studied is typically dosed as dexamethasone base, and use of Dexamethasone Sodium Phosphate for this purpose should follow current treatment protocols and physician judgment.

Dexamethasone Sodium Phosphate is not effective against systemic fungal infections and is not an antibiotic.

Dosage of Dexamethasone Sodium Phosphate is individualized based on the condition being treated, its severity, and the patient's response, and should always be the lowest dose that achieves the desired clinical effect.

Pediatric dosing

Approximately 0.02-0.3 mg/kg/day (or 0.6-9 mg/m2/day) IV or IM in divided doses, adjusted to the specific disease and response; lower end of the range preferred whenever possible given growth-suppression risk with prolonged use.

Renal/hepatic impairment

No formal fixed dose adjustment is well established, but Dexamethasone Sodium Phosphate should be used cautiously and at the lowest effective dose in patients with hepatic impairment (reduced metabolism may prolong effect) and in those with significant renal impairment (fluid/electrolyte monitoring advised).

Administration

Administer by slow IV injection/infusion, IM injection, or by intra-articular, intralesional, or soft-tissue injection, using strict aseptic technique. Do not administer via the epidural route (associated with serious neurologic events). Prolonged courses should be tapered gradually rather than stopped abruptly (see Precautions and Warnings).

Side effects of Dexamethasone Sodium Phosphate are generally related to dose and duration of therapy. Short courses at low doses are usually well tolerated.

• Common: insomnia, increased appetite, mood changes/nervousness, fluid retention, facial flushing, indigestion, elevated blood glucose
• Endocrine/metabolic: adrenal suppression, Cushingoid features, hyperglycemia, sodium/fluid retention, hypokalemia
• Musculoskeletal: muscle weakness/myopathy, osteoporosis, vertebral compression fractures, avascular necrosis of bone (with prolonged use)
• Gastrointestinal: peptic ulceration (especially with NSAIDs), abdominal distension, pancreatitis (rare)
• Dermatologic: impaired wound healing, thin fragile skin, bruising, acne
• Ophthalmic: posterior subcapsular cataracts, increased intraocular pressure/glaucoma (with prolonged use)
• Psychiatric: mood swings, euphoria, insomnia, and rarely, severe depression or psychotic manifestations
• Immune: increased susceptibility to and masking of infections
• Injection-site: pain, atrophy, or hyperpigmentation at repeated local injection sites

Patients should report unusual symptoms promptly; most systemic side effects are more likely with high doses or prolonged therapy rather than short courses.